- Occurring every Tuesday between October 6 and December 8
- Each webinar to cover key formulation, process and production challenges for complex oral and parenteral drug products
- More than a dozen technical experts from Evonik and other industry partners to present, and be available for questions
Evonik invites pharmaceutical and biotechnology professionals to join it for a free ten-part webinar series on advanced drug delivery that will occur every Tuesday between October 6 to December 8.
As a global integrated CDMO leader for advanced drug delivery, Evonik will use the webinar series to review key formulation, process and manufacturing challenges for complex oral and parenteral drug products. More than a dozen technical experts from Evonik, as well as other industry partners, will share their knowledge and be available to answer questions. Each webinar will commence at 10:00 a.m. EDT / 4:00 p.m. CEST. Registration is via Evonik’s own platform onCare.
“Many of our pharmaceutical and biotechnology customers and other industry professionals from around the world are hungry to learn more about a series of key trending topics for advanced drug delivery,” said Mr. Paul Spencer, Head of Pharma Polymers and Services for Evonik’s Health Care business line. “With this ten-part webinar series, we look forward to sharing industry best practices and relevant case studies that can help them address specific formulation, process and manufacturing challenges for complex parenteral and oral drug products.”
The ten-part series will begin on Tuesday, October 6 with six weekly webinars dedicated to parenteral drug products. Topics will include polymeric microparticle and nanoparticle-based drug products, ocular drug delivery, parenteral excipients for extended release, and lipid nanoparticles for use with COVID-19 vaccines, nucleic acids and small molecules.
From November 3, four additional webinars will occur every Tuesday covering oral drug delivery topics including delayed release formulations, advanced colon targeting and reformulation strategies.
Evonik’s Health Care business line, which is part of the Nutrition and Care division of Evonik, is one of the world’s leading integrated CDMOs for complex oral and parenteral drug products that require advanced drug delivery solutions. It is also one of the world’s largest pharmaceutical suppliers of generic APIs, amino acids and cell culture ingredients, and a top three global CMO for APIs and intermediates.
To register for one or more webinars, click on the webinar title:
Tuesday, October 6 | 10 a.m. EDT / 4 p.m. CEST
Tuesday, October 13 | 10 a.m. EDT / 4 p.m. CEST
Tuesday, October 20 | 10 a.m. EDT / 4 p.m. CEST
Tuesday, October 27 | 10 a.m. EDT / 3 p.m. CET
Tuesday, November 3 | 10 a.m. EST / 4 p.m. CET
Tuesday, November 10 | 10 a.m. EST / 4 p.m. CET
Tuesday, November 17 | 10 a.m. EST / 4 p.m. CET
Tuesday, November 24 | 10 a.m. EST / 4 p.m. CET
Tuesday, December 1 | 10 a.m. EST / 4 p.m. CET
Tuesday, December 8 | 10 a.m. EST / 4 p.m. CET
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, day by day.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around €4.6 billion in 2019.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.